ZYDUS HOSPIRA ONCOLOGY PRIVATE LIMITED,AHMEDABAD vs. ASSESSMENT UNIT, IT DEPARTMENT PRESENT JURISDICTION THE DY. CIT, CIRCLE-4(1)(2), AHMEDABAD

PDF · subscribers
ITA 1521/AHD/2024Status: DisposedITAT Ahmedabad03 November 2026AY 2020-2137 pages
AI SummaryPartly Allowed

What did the Tribunal hold?

The Tribunal consolidated the appeals for common disposal. For ITA 87/AHD/2022 (AY 2017-18), the primary ground concerning the transfer pricing adjustment on international transactions of sales to AE under LDA was dismissed. The Tribunal noted that this ground was identical to a ground in ITA 1521/AHD/2024 and applied its decision in that case mutatis mutandis. In ITA 1521/AHD/2024 (AY 2020-21), grounds 1 and 3 were not pressed and were dismissed. Ground 2, relating to the transfer pricing adjustment, was dismissed following the decision in ITA 87/AHD/2022. Grounds 4 to 7, concerning penalty proceedings and interest levies, were considered consequential and required no adjudication. Consequently, ITA 1521/AHD/2024 was dismissed. The judgment states that ITA 87/AHD/2022 was partly allowed, while ITA 1521/AHD/2024 and ITA 2123/AHD/2024 were dismissed. The specific reasons for ITA 87/AHD/2022 being partly allowed are not detailed in the provided extract, beyond the dismissal of the primary TP ground.

What were the facts?

The appeals by Zydus Hospira Oncology Pvt. Ltd. (the Assessee) are against assessment orders passed by the Dy. Commissioner of Income Tax (the Revenue) for Assessment Years 2017-18, 2020-21, and 2021-22. The orders were passed pursuant to directions from the Dispute Resolution Panel (DRP). The Assessee is represented by Shri S N Soparkar, Sr Advocate, and the Revenue by Shri R.V.Aroon Prasaad, CIT-DR. The appeals involve common issues and are being disposed of together. The core dispute in ITA 87/AHD/2022 (AY 2017-18) concerns an adjustment of Rs. 16,69,00,000 in relation to international transactions of sales to an Associated Enterprise (AE) under a Licence Distribution Agreement (LDA). Other grounds in this appeal relate to depreciation on software, claim under Section 10AA, and charging of interest under Sections 234B and 234A, and MAT credit set-off.

What were the issues?

1. Whether the Tribunal had to decide if the adjustment of Rs. 16,69,00,000 made by the Assessing Officer (AO) in relation to the international transaction of sales to an Associated Enterprise (AE) under the Licence Distribution Agreement (LDA) was correct, concerning Assessment Year 2017-18 (ITA 87/AHD/2022), and similar adjustments for other assessment years (ITA 1521/AHD/2024 and ITA 2123/AHD/2024)? Assessee's contentions: - The pricing mechanism in the LDA, agreed between unrelated Joint Venture Partners (Cadila Healthcare Limited and Hospira Australia Pty Limited) in the Joint Venture Agreement (JVA), should be considered at arm's length. - The AO erred in stating that JV partners lose their individual status in the JV entity (ZHOPL) and in attributing rewards to ZHOPL for R&D functions and Product Intellectual Property (IP) of Hospira Australia Pty Limited. - The AO wrongly held the appellant as the owner of crucial intangibles and attributed rewards for them to the appellant. - The AO failed to observe the overall value chain and incorrectly concluded that AEs were merely engaged in distribution activities. - The AO incorrectly considered the appellant's manufacturing facility as a significant intangible asset. - The AO erred in rejecting the appellant's approach of selecting itself as the tested party and adopting the 'Other Method' as the most appropriate method in the Transfer Pricing (TP) study. - The AO erred in considering the Profit Split Method (PSM) as the most appropriate method and arbitrarily applied the Rolls Royce Plc ruling, allocating profit in the ratio of 50:15:35. - Without prejudice, the AO erred in applying PSM by not undertaking a fresh benchmark, relying on comparables from AY 2012-13, considering incomparable business activities and only one jurisdiction (Netherlands) for comparables against AEs in different regions, and considering only salary expenses of one AE instead of total marketing and distribution costs. - The AO erred in allowing depreciation on software at a lower rate than claimed, contrary to Rule 5 of the Income-tax Rules and a previous ITAT decision in the assessee's own case. - The AO erred in not allowing the claim under Section 10AA. - The AO erred in charging interest under Sections 234B and 234A. - The AO erred in not giving set-off of MAT Credit of earlier years under Section 115JAA. - The AO erred in initiating penalty proceedings under Section 270A. Revenue's contentions: - Not recorded in the judgment.

Which sections of the Income-tax Act were involved?

Section 32,Section 10AA,Section 115JAA,Section 143(3),Section 144C(13),Section 234A,Section 234B,Section 234D,Section 270A

AI-generated summary — verify with the full judgment below

Income Tax Appellate Tribunal, AHMEDABAD BENCHES, AHMEDABAD

Before: DR. BRR KUMAR & SHRI SANJAY KUMAR

For Respondent: Shri R.V.Aroon Prasaad,CIT-DR
Pronounced: 03.11.2026

Heard together (3 matters)

ITA 87/AHD/2022
ITA 1521/AHD/2024
ITA 2123/AHD/2024

Read from the judgment's own cause title. This page is filed under one of them.

आयकर अपील"य अ"धकरण, अहमदाबाद पीठ", अहमदाबाद INCOME TAX APPELLATE TRIBUNAL, AHMEDABAD BENCHES, AHMEDABAD BENCH: D BEFORE DR. BRR KUMAR, VICE PRESIDENT AND SHRI SANJAY KUMAR, JUDICIAL MEMBER ITA 87/AHD/2022 (िनधा"रण वष"/Assessment Year: 2017-18) Zydus Hospira Oncology Pvt. The Dy. Commissioner Of Ltd., Income Tax, Circle-4(1)(2), Plot No.3, Pharmez,-Special Pratyaksh Kar Bhavan, Near Econimic Zone,, Sarkhej Bawala Panjarapole, Ambawadi, Highway (Nh No.8a), Vill. Matoda, Tal. Sanand,, Ahmedabad-382213, Gujarat

ITA 1521/AHD/2024 (िनधा"रण वष"/Assessment Year: 2020-21) Zydus Hospira Oncology Private The Dy. CIT, Circle-4(1)(2) Limited Pratyaksh Kar Bhavan, Plot No. 3, Pharmez-Special Panjarapole , Ambawadi Economic Zone, Sarkhej Bavla Highway (Nh 8a), Matoda, Sanand, Ahmedabad-382213, Gujarat

- 2– ITA 2123/AHD/2024 (िनधा"रण वष"/Assessment Year: 2021-22) Zydus Hospira Oncology Private The Dy.CIT, Circle-4(1)(2) Limited. Pratyaksha Kar Bhavan Plot No. 3, Pharmez-Special ,Panjarapole, Ambawadi Economic Zone, Sarkhej Bavla Highway (Nh 8a), Matoda, Sanand, Ahmedabad-382213, Gujarat

सुनवाई की तारीख / Date of conclusion of hearing: 06.08.2026 घोषणा की तारीख / Date of pronouncement: 03.11.2026 आदेश / ORDER PER SANJAY KUMAR, JUDICIAL MEMBER:- The above appeals are directed against separate assessment orders passed by the AO, pursuant upon the directions of Ld. DRP, tabulated herein below. Since the appeals pertains to the same Assessee and common issues are involved in all these appeals therefore, for the sake of convenience, these appeals are being disposed of together by way of common order. ITA 87/AHD/2022 Impugned order dated 10.02.2022. (AY: 2017-18) ITA 1521/AHD/2024 Impugned order dated 28.01.2024. (AY: 2020-21) ITA 2123/AHD/2024 Impugned order dated 23.10.2024. (AY: 2021-22)

- 3–

ITA No. 87/AHD/2022 (Assessment Year 2021-22): 2. We will first take up ITA No. 87/AHD/2022. 3. The grounds taken in ITA No. 87/AHD/2022 read as under: “1. On the facts and in the circumstances of the case and in law, the Learned Additional/Joint/Deputy/Assistant Commissioner of Income-tax, National Faceless Assessment Centre, Delhi ('the Ld. AO') under the directions of Honourable Dispute Resolution Panel (DRP), erred in making an adjustment of Rs. 16,69,00,000 in relation to the international transaction of sales to the Associated Enterprise (AE) under the Licence Distribution Agreement.

On the facts and in the circumstances of the case and in law, the Ld. AO has erred in following

1.1. Disregarding that the pricing mechanism incorporated in Licence Venture Partners (i.e. Cadila Healthcare Limited (CHL) and Hospira Australia Pty Limited (HAPL)) in the Joint Venture Agreement (JVA) and the same should be considered at arm's length.

1.2. Stating that JV Partners lose their individual status once they represent in the form of ZHOPL (i.e. JV) and attributing rewards to ZHOPL for Research and Development (R&D) functions and Product Intellectual Property(IP) of HAPL..

1.3. Holding the appellant as the owner of the most crucial and valuable intangibles and wrongly attributed reward for the same to the Appellant.

1.4. Not observing the overall value chain of the business and incorrectly concluded that the AEs are merely engaged in distribution activities and they should be rewarded only for distribution function.

- 4–

1.5. Considering the Appellant's approved (approved by USFDA, Health Canada and MHRA, UK) manufacturing facility as significant intangible asset.

1.6. Rejecting the Appellant's approach of selecting itself as the tested party and adopting 'Other Method' as the most appropriate method, in the Transfer Pricing (TP) Study/Documentation.

1.7. In considering Profit Split Method (PSM) as the most appropriate method to determine Arm's Length Price of international transaction of sale of six formulations products to HEBV.

1.8. Arbitrarily applying Rolls Royce Plc ruling (M/s Rolls Royce Plc vs The Dy. Director of Income Tax, New Delhi, 2007-TII-32-ITAT-DEL-INTL) to the Appellant's case fact pattern and allocated profit in the ratio of 50: 15: 35 for manufacturing function, R&D activity and marketing activity respectively.

1.9. Without prejudice to the above, on the facts and in the circumstances of the case and in law, the Ld. A.O. erred in applying PSM

1.9.1. Not undertaking a fresh benchmark as required by India Transfer pricing regulation and relying on the same comparables selected by the Ld. Transfer Pricing Officer in AY 2012-13. 1.9.2. By considering comparables engaged in incomparable business activities to that of AEs and only from one jurisdiction, i.e. Netherland, against Appellant's AEs, located in different geographical regions viz. Europe, USA etc.

- 5– 1.9.3. By considering only salary expenses of one of the AEs and not considering the entire marketing and distribution cost of all the AEs that are involved in the distribution activity.

The Appellant prays that the addition made by the Ld. A.O. in relation to the international transaction of sales to AE is to be deleted.

2.

That the learned A.O. erred in law and on facts in allowing depreciation u/s 32(1) on the cost of Software at Rs.9,74,548/- instead of Rs.23,38,916/- claimed by the Appellant. The Ld. A.O. has erroneously applied the rate of 25% / 12.5% as applicable to 'Intangible assets' as against the correct rate of 60%/30% prescribed under the "Clause -III - Machinery and Plant item No. 5 'Computer including computer software-60%" in New Appendix-1 Table of Rates at which Depreciation is Admissible' to Rule 5 of the Income-tax Rules. The similar issue involving identical facts has been decided in favor of the Assessee by the Hon'ble ITAT, Ahmedabad in its own case for AY 2010-11 and AY 2011-12. 3. That the learned A.O. erred in law and on facts in not allowing Appellant's claim u/s.10AA of Rs.41,22,64,071/- while computing the tax payable even though the same has not been disturbed during the course of Assessment Proceedings and as a consequent to this erroneously charged excess tax payable under normal provisions of the Income-tax Act by Rs.14,26,76,350/- (Rs.41,22,64,071 X 34.608%).

4.

That the learned A.O. erred in law and on facts in charging interest u/s.234B of Rs.8,00,89,609/-.

5.

That the learned A.O. erred in law and on facts in charging interest u/s.234A of Rs.13.57,451/- even though Appellant has duly submitted its Income-tax Return within the due date.

- 6–

6.

That the learned A.O. erred in law and on facts in not giving set-off of MAT Credit of earlier years u/s. 115JAA against the tax payable under normal provisions of the Income-tax Act.

7.

That the learned AO erred in law and on facts in concluding that the Appellant has furnished inaccurate particulars of income, and hence directed to initiate penalty proceedings u/s 270A.

The appellant prays that leave may be granted to add, amend or alter any of the grounds at any time before the final hearing of the appeal.

Annexure – 1 [Additional Ground]

Without prejudice to the grounds already raised in the Appeal memo, the Appellant submits that:

1.

On the facts and in the circumstances of the case and in law, the final assessment order dated 10 February 2022 passed by the Learned Assessing Officer (Ld. AO) under section 143(3) read with section 144C(13) of the Act is barred by limitation and therefore, is void-ab-initio, bad in law and is liable to be quashed.

The Appellant prays that the assessment order be quashed, and the entire addition made by the Ld. AO/Ld. TPO be deleted.

The Appellant craves leave to add, substitute, amend, delete, or otherwise modify any of the grounds of appeal stated hereinabove before commencement of or at the time of hearing. 4. First, we will take Ground No. 1 of the present appeal.

- 7– 4.1. Brief facts relating to this ground are that the TPO for the present Assessment Year 2017-18 has relied upon its order for preceding Assessment Years, including the Assessment Year 2013-14, as the issue remained identical in all these years. The background facts as recorded in the order of the TPO are as under:

“LDA agreement - Concept of True up charges:

4.

The assessee company is a 50:50 Joint Venture incorporated vide agreement dated 18.05.2005 between Cadila Healthcare Limited and Mayne Pharma Pty Ltd for development and manufacture of products at the facilities and other injectable cytotoxic products in India (para 16.1 of JV agreement). In the year 2007, Mayne Pharma Pty. Limited was taken over by Hospira Australia Pty Limited (HAPL). The assessee company entered into a License Distribution Agreement (LDA) dated 25/09/2008 with Hospira Enterprises, BV (HEBV) for distribution of six products namely (i) Docetaxel (ii) Epirubicin (iii) Gemcitabine (iv) Irinotecan (v) Oxaliplatin & (vi) Topotecan. As per the LDA agreement, the HEBV & affiliates were supposed to distribute the products of the assessee within the specified territories. As per the JV agreement, both the partners have contributed their IPRs relating to product development and manufacturing activity and it was agreed that the 6 products manufactured by ZHOPL would be distributed by HEBV and its affiliates in the Hospira territory. ZHOPL was to be compensated at the rate of cost + 20% or 50% of net sale value made by HEBV and its affiliates whichever is higher. In this arrangement, the remuneration received by ZHOPL over and above cost + 20% is termed as true up charges.

5.

During the year under consideration, the assessee has sold drugs/injectables worth Rs. 278.28 Crore to HEBV (AE) for distribution in Hospira Territory as per the LDA agreement. As per the terms of LDA agreement, ZHOPL was to be compensated at the rate of cost + 20% or 50% of net sale value made by HEBV and its affiliates whichever is higher. In this arrangement, the remuneration received by ZHOPL over and above cost+ 20% is called as true up charges. ZHOPL was established as a 50:50 JV between CHL and HAPL in May 2005. It was agreed in the JVA that, ZHOPL will manufacture the six formulation products from its approved facility and sell to JV partners and their affiliates at the agreed pricing mechanism.

- 8– 6. CHL and HAPL (i.e. two third parties) hold equal stake in ZHOPL and any agreement between them is claimed by the assessee to be an understanding/arrangement between two unrelated parties. The assessee further claimed that since the terms of the transaction between ZHOPL and AEs under LDA operation, in substance were determined in JVA by CHL and HAPL, two unrelated parties, hence, the transaction under LDA operation is also to be considered at arm's length. In view of the above, the assessee claimed that the price of above international transaction was at arm's length as pricing as it was stated to have been agreed between two unrelated parties i.e. CHL and HAPL and 'Other Method' was taken to be the most appropriate method of the methods prescribed under Section 92C read with proviso to Section 92C(2) of the Income Tax Act, 1961.” 4.2. Following the earlier years, the TPO selected Profit Split Method (PSM) as the Most Appropriate Method (MAM) and split the profit in a 65:35 ratio, i.e., 65% of the profit was attributed to the Assessee. Since the manufacturing activities have been carried out by one member of the JV, namely, Cadila Healthcare Limited, by using the manufacturing related IPRs, and the other member of the JV, i.e., Hospira Australia Pte. Limited, performed the function of the product related IPR and IPR to Para IV USFDA partner, the AO accordingly split the residual profit in the ratio of 65:35 and suggested an adjustment of Rs. 16,69,00,000/-.

4.3. The objections were raised before the Ld. DRP. Relying upon its directions for Assessment Year 2013-14, the Ld. DRP rejected the objections made by the Assessee on this count.

4.4. Consequently, the Assessment Order was passed by the AO, against which the Assessee is in appeal before us.

- 9– 5. We have heard Shri S.N. Soparkar, Ld. Senior Advocate for the Assessee, and Shri R.V. Aroon Prasaad, Ld. CIT-DR for the Revenue, at some length.

6.

The submissions made by Mr. Soparkar, Ld. Senior Advocate for the Assessee, have been recapitulated in a note dated 12.08.2026 filed on record, which reads as under: “BEFORE THE HON'BLE INCOME TAX APPELLATE TRIBUNAL, AHMEDABAD BENCH "D" In the Matter of: Zydus Hospira Oncology Private Limited ("Appellant" / "ZHOPL") Relating to AY 2017-18 Relating to AY 2020-21 ITΑ . 1521/AHD/2024 (Appeal of the Appellant) Relating to AY 2021-22 BRIEF NOTE ON FACTS AND SUBMISSIONS ADVANCED DURING THE COURSE OF HEARING 1. The captioned appeals were listed for hearing before the Hon'ble Ahmedabad Bench "D" on 6 August 2026 and were thereafter marked as heard. 2. For the convenience of this Hon'ble Bench, the Appellant is placing on record the present note setting out (i) the relevant factual background, (ii) the principal submissions advanced during the hearing, and (iii) the judicial precedents relied upon for respective transfer pricing grounds as follows: AY 2017-18-Ground No 1 AY 2020-21- Ground No 1 AY 2021-22- Ground No 2 3. As submitted during the course of hearing, the issues arising in Assessment Year ("AY") 2020-21 and AY 2021-22 are substantially similar to those involved in AY 2017-18. Accordingly, unless otherwise indicated, the factual and legal submissions contained in this note apply mutatis mutandis to all three assessment years. 4. Background and facts of the case

- 10– The Appellant is a joint venture between Cadila Healthcare Ltd (CHL) (now Zydus Lifesciences Limited (ZLL)) and Hospira Australia Pty Limited (HAPL) (formerly known as Mayne Pharma Pty Ltd. and now part of Pfizer Group). The Appellant during the years under consideration was engaged in manufacturing of anti-cancer formulations in Pharmez, Special Economic Zone (SEZ) near Ahmedabad, Gujarat. 4.1. Joint Venture Agreement entered in May 2005 (Page no. 547 to 662 of the Paper book) • Cadila Healthcare Ltd (CHL) and Hospira Australia Pty. Limited entered into a 50:50 Joint Venture Agreement (JVA) in May 2005 with the intention to construct manufacturing facility for the production of generic formulation products • It was agreed in the JVA that the Appellant will manufacture the formulation products from its approved facility using Intellectual Property (IP) of the JV Partners and Hospira (where Hospira refers to HAPL, Hospira Enterprise BV, Hospira Inc and its affiliates) shall sell the products under Hospira's brand/tradenames in its agreed territories. (Clause 18 of JVA, Page no. 578 and 579 of Paper book) • The following pricing mechanism was agreed in the JVA for the supply of formulation products from ZHOPL to Hospira. (two unrelated parties). (Clause 18.1 of JVA, Page no. 578 of Paper book)

"ZHOPL would get an assured return of 20% of its cost or 50% of the Net Sales Price, whichever is higher."

• Accordingly, Zydus Hospira Oncology Private Limited (hereinafter referred to as 'the Appellant', 'the Company', or 'ZHOPL') was incorporated in 13 June 2005. 4.2. License Distribution Agreement entered in September 2008 (Page no. 663 to 741 of the Paper book) • For purchase of goods from ZHOPI, Hospira identified HEBV as the sourcing and logistic entity. Accordingly, a License and Distribution Agreement (LDA) was entered between HAPL, ZHOPL, and HEBV, Netherland in September 2008. The LDA gives effects to the pricing mechanism already agreed in the JVA between CHL and HAPL. • ZHOPL commenced commercial production in May 2009 and supplies six formulation products to HEBV. HEBV distributes the ZHOPL sourced products through sales and marketing affiliates of Hospira and third-party distributors. 4.3. Appellant's approach in the TP study analysis. • CHL and HAPL (i.e. two third parties) holds equal stake in ZHOPL. Any agreement between CHL and HAPL is considered as an understanding between two unrelated parties. Further, the terms of the transaction between ZHOPL and Hospira under discussion, were determined in JVA by CHL and HAPL (two unrelated parties).

- 11– • In view of the above, the Appellant in its TP documentation has considered the above international to be at arm's length as the pricing of the transaction was agreed between two unrelated parties i.e. CHL and HAPL selecting Other method as the most appropriate method of the methods prescribed under Section 92C of the Act. 4.4. TP Assessment proceedings However, the Ld. TPO during the assessment placed reliance on earlier year TPO orders and rejected the Appellant's approach and adopted Profit Split Method (PSM) as most appropriate method. Accordingly, the Ld. TPO in respective years proposed TP adjustments under as follows: Assessment Year Amount of TP adjustment (INR in Crores) 2017-18 16.69 2020-21 28.52 2021-22 45.61

As against the AO's draft order (incorporating the above TP adjustments), the Appellant filed objections before Hon'ble DRP wherein DRP upheld the adjustment made by the TPO by relying on the direction of the DRP in earlier years. <<This space is left blank intentionally>> 5. Submissions advanced on behalf of the Appellant against aforesaid TP adjustments 5.1. Pricing mechanism agreed in JVA between two unrelated parties (i.e., CHL and HAPL) to be considered as arm's length price for transaction of the Appellant under LDA operations (Ground No 1.1) • The JVA entered in 2005 between CHL and HAPL between two unrelated parties, clearly identified the pricing mechanism for distribution of products by the Appellant to Hospira which can be observed from Clause 18.1 of the JVA reproduced below: "18.1 Sale of Products Subject always to applicable law, their respective existing supply agreements listed in Schedule 9 and compliance with the transfer price regulations of India, both Parties shall negotiate and finalise Licence and Distribution Agreements with the Company for the sale by the Company and the purchase by the Parties (or their Affiliates) of all Products (Fill and Finish) manufactured at the Fill and Finish Plant at a price equal to 50 per cent of the Net Sales Price but not less than 120 per cent of the cost price to the Company to manufacture such Products (Fill and Finish)."

- 12– (Page no. 578 of the Paper book) • The LDA entered in September 2008 between the Company, HEBV and HAPL only incorporated the pricing mechanism agreed in the JVA and outlined the other terms and conditions in relation to sale, promotion, marketing and distribution of the products by HEBV in Hospira territories. The relevant definitions of prices mentioned in the LDA are reproduced below: "1.1 Definitions Final Price means for each Presentation of Products the higher of the Floor Price and 50% of the Actual Net Sales Price as determined according to clause 8.3; Floor Price means one hundred and twenty per cent (120%) of the Cost of Product, as determined according to clause 8.2"

• The above clearly demonstrates that the terms of the transaction between the Appellant and the AE i.e. Hospira under LDA operation, were primarily determined in JVA between CHL and HAPL (two unrelated parties) and the LDA merely reiterated the agreed pricing mechanism of JVA. • CHL and HAPL holds 50:50 stake in ZHOPL. Such co ownership of CHL and HAPL in ZHOPL does not trigger conditions prescribed for identification of 'Associated Enterprises' in provisions of the Act. • Further, HAPL and CHL do not hold any shares in each other and there is no common control they cannot be considered as AEs of each other as per section 92A(2)(b) and 92A(f) of the Act. • Hence, the JVA between CHL and HAPL should be considered as an arrangement between two unrelated parties and the pricing mechanism agreed therein and followed in the LDA should be considered to be in accordance with the arm's length principle. • The above principle was also held in following tribunal rulings relied upon by the Appellant to support its contentions: Satyam Venture Engineering Services Private Ltd vs. ACIT, (ITA No. 1590/Hyd/2010) (Page no. 1-10 of the Case Law Paper book) Kalyani Hayes Lemmerz Ltd vs DCIT Circle-9, Pune [2018] 89 taxmann.com 441 (Pune - Trib.) (Page no. 11-20 of the Case Law Paper book) Ballast Nedam Dredging vs Additional Director of Income-tax (IT) 3(2) [2013] 32 taxmann.com 317 (Mumbai - Trib.) (Page no. 21-42 of the Case Law Paper book) • Further, it was also submitted to the Ld. TPO/AO that there has been no change in the functional analysis and the pricing mechanism for the relevant international transaction from the inception of the LDA. It is worthwhile noting that the said transfer pricing policy has been accepted by the Ld. TPO for the AY 2010-11 and AY 2011-12. (Page no 357 to 360 of the Paper book). Conclusion

- 13– In view of the above, the Appellant respectfully submits that the pricing mechanism governing the international transactions between the Appellant and Hospira in relation to the LDA operations was, in substance, established under the Joint Venture Agreement ("JVA") entered into between two independent and unrelated joint venture partners, namely CHL and HAPL. Accordingly, the pricing of such transactions was determined in an uncontrolled environment and reflects commercially negotiated terms between independent parties. Therefore, the impugned international transactions should be regarded as being consistent with the arm's length principle. 5.2. Wrongful application of Profit Split Method (PSM) by Ld. AO/TPO (Ground No 1.2 to 1.8 of appeal for AY 2017-18) 5.2.1. ZHOPL is not the owner of Intellectual Property (IP) Product IP • The JVA entered in 2005 between CHL and HAPL have categorized the Product IP into two categories namely (i) Background IP and (ii) Foreground IP. The LDA merely makes reference to JVA for the above category of IPs and there definitions. • The definitions of the said IPs are reflected in clause 1.1 of the JVA (Page no. 551 and 554 of the Paper book respectively). The relevant definitions as per clause 1.1 JVA are reproduced below: "1.1 Definitions "Background Intellectual Property" means any Intellectual Property, other than Foreground Intellectual Property, existing or arising in respect of the Products, which is intended to be used by the Company in the Business. "Foreground Intellectual Property" means any Intellectual Property that arises or is obtained or developed by, or by a contractor on behalf of, the Company in conducting the Business." • Further, clause 23.1.1 of the JVA (Page no. 583 of the Paper book) states that HAPL being the developer and legal owner the Background IP has provided the Appellant a royalty-free, non-transferable, worldwide license to use its Background IP in relation to the production, manufacture, distribution, marketing, selling, advertising and promotion of products. The relevant clause has been reproduced below: "23.1.1 As of the Further Capital Contribution Date, Mayne grants the Company a royalty-free, non-transferable, worldwide licence to use its Background Intellectual Property in relation to the production, manufacture, distribution, marketing, selling, advertising and promotion of products pursuant to this Agreement." • Further, clause 11.2 (a) of the LDA (Page no. 689 of the Paper book) also states that the Appellant owns all rights, title and interest in all Intellectual Property Rights in the Product (excluding Background Intellectual Property). Hence, ZHOPL does not own any Background intellectual property. • As far as Foreground IP (Le. IP other than Background IP is concerned), it is the Appellant's humble submission that it does not have any R&D personnel

- 14– and has not performed any R&D activities till date, nor has it undertaken any activity which could lead to generation of any Foreground IP. • The above is also evident from the appellant financial statements (Page no. 164 to 225 of the Paper book) wherein it can be seen that it has not incurred any R&D expenditure that would tantamount to development of any Foreground IP. • IP owned and developed by Hospira Furthermore, please refer to the terms and conditions w.r.t licensing of the IP, which also reflects that the six formulations products were developed by HAPL at its Mulgrave facility in Australia even before ZHOPL was operational. (Page no.

to 790 of the Paper book) Additionally, a reference is also to be made to documents reflecting transfer of the technology by HAPL to the Appellant for production of the six formulation products. (Page no. 793 to 804 of the Paper book) In view of the above, it is clear that HAPL is the developer and legal owner of the Background IP, and the Appellant has been merely provided with license to use the said IP. Marketing authorization and Branding • Hospira has exclusive marketing and distribution rights in their respective territories (clause 18.3 of JVA-Page no. 578 to 579 of Paper book and clause 10 of LDA - Page no. 688 of the Paper book) and hence, only they can commercialize the six formulations products in the market as they have obtained required marketing authorizations from various regulatory authorities to sell produets in their territories. ZHOPL is only required to support AE in filing dossiers with the regulatory authorities to obtain marketing authorizations in the respective territories. This does not confer ownership of intellectual property rights. (clause 23.1.4 of JVA - Page No. 583 of Paper book and clause 4.2 of LDA- Page no. 677 to 678 of Paper book) • Further, as per clause 18.4.1 of the JVA (Page no. 579 of the Paper book), Hospira uses its own name to brand Products in Hospira territories. Conclusion In view of the above, the economic and legal ownership of intangibles between parties between ZHOPL and Hospira can be summarized as follows: Name of Party Intangibles owned Hospira Product IP Marketing Authorization Brand ZHOPL No intangibles

5.2.2. PSM Method cannot be applied

- 15– • PSM is applied when transacting entities are owning unique intangibles, making valuable contributions or transactions are highly integrated. • In the present fact pattern described in para 5.2.1 above, activities of ZHOPL and Hospira are not integrated. ZHOPL is a manufacturer and it manufactures six formulation products and sells to Hospira and doesn't own any intangible whereas Hospira owns Product IP, Marketing IP, Brand and distributes products across the globe. • Reliance may be placed in this respect on the OECD TP guidelines and UN TP manual: OECD Guidelines on PSM method, Para 2.115 "...A transactional profit split method may also be found to be the most appropriate method in cases where both parties to a transaction make unique and valuable contributions (e.g. contribute unique intangibles) to the transaction, because in such a case independent parties might wish to share the profits of the transaction in proportion to their respective contributions and a two-sided method might be more appropriate in these circumstances than a one-sided method. In addition, in the presence of unique and valuable contributions, reliable comparables information might be insufficient to apply another method. On the other hand, a transactional profit split method would ordinarily not be used in cases where one party to the transaction performs only simple functions and does not make any significant unique contribution (e.g. contract manufacturing or contract service activities in relevant circumstances), as in such cases a transactional profit split method typically would not be appropriate in view of the functional analysis of that party."

UN TP Manual on PSM method, Para B.3.3.17.2. "The (Residual) Profit Split Method is typically used in complex cases where both sides to the controlled transaction own valuable intangible property (e.g. patents, trademarks and trade names). If only one of the associated enterprises owns valuable intangible property, the other associated enterprise will be the tested party in an analysis using the cost plus, resale price or transactional net margin methods." • In the instant case, the Appellant under LDA operations does not qualify for PSM in view of following points: i. ZHOPL and AEs operations are not integrated at all; ii. ZHOPL manufactures six formulation products whereas Hospira owns Product IP, holds marketing authorizations, sells under its brand name and distributes products across the globe; iii. Hence, it is substantiated that ZHOPL has less complex functions and assumes lesser share of risks. Accordingly, the said international transaction cannot be said to be integrated for applying PSM. 5.2.3. Application of ratio (65:35) relying on the case of M/s Rolls Royce Ple is not arbitrary and not warranted

- 16– It is the humble submission of appellant that the methodology applied by the Ld AO/TPO for applying residual profit split based on ratio laid down in M/s Rolls Royce Plc is inappropriate due to following reasons: • The Rolls Royce Ple ruling was of a foreign entity for its alleged Permanent Establishment ('PE') in India and attribution of profits thereof whereas ZHOPL is an Indian entity maintaining separate books of account and earning arm's length reward for the functions carried in India. • The Permanent Establishment of the foreign entity operating in automobile industry as against appellant who operates in pharmaceutical industry. • The referred ruling, didn't provide any basis for allocation of profit in the ratio of 65:35:15 which cannot be applied directly to the Appellant on an ad hoc basis. Hence, ratio laid down in Rolls Royce Ple ruling cannot be applied in ZHOPL's case, 5.3. Application of TNMM method considering ZHOPL as tested party Without prejudice to the above, it is the humble submission of the Appellant that, since PSM cannot be applied in the instant case based on abovementioned submissions in section 5.2 above, Transactional Net margin method (TNMM) may be selected as most appropriate method selecting ZHOPL as tested party and testing its OP/TC margins of the LDA segment with that of comparable companies. ZHOPL's operating margins (OP/TC) under LDA segment (including true-up) for the years under consideration ranges from 48.56% to 87.74% which should meet the arm's length requirements as per India TP regulations. ALL OF THE ABOVE IS MOST HUMBLY SUBMITTED ON BEHALF OF THE ASSESSEE” 6.1. Essentially, the order of the TPO has been challenged on the following two counts:

A. The Assessee claims that the commercial terms and profit sharing formula were originally conceived and settled under the Joint Venture Agreement of May, 2005 between CHL and HAPL, which were two unrelated entities, and therefore the appellant in its TP documentation had rightly considered the international transaction between them to be at arm's length, selecting 'Other Method' as the Most Appropriate Method out of the methods prescribed u/s 92C of the Act. It was submitted that the TPO was not right in selecting the PSM as MAM u/s 92C of the Act.

- 17– B. The application of the ratio 65:35, relying on M/s. Rolls Royce Plc, is arbitrary, as it performs less complex functions and assumes a lesser share of the risk.

7.

Per contra, Mr. R.V. Aroon Prasaad, Ld. CIT-DR, submitted that the transaction in question is governed by the License Distribution Agreement (LDA) dated 25.09.2008 with Hospira Australia Pty. Limited (HAPL). The parties to the transaction being AEs in terms of Section 92 of the Act, the income arising from such transaction has to be necessarily computed having regard to the arm's length price. He submits that the method adopted by the Assessee in this case, i.e., relying upon the agreement of the year 2005, is not a prescribed method u/s 92C of the Act, and hence the TPO has rightly invoked Profit Split Method (PSM) as the Most Appropriate Method to determine the arm's length price for this transaction. He further submits that in the Rolls Royce case (supra), the Tribunal allocated 50% of the profits towards manufacturing activities, 15% of the profit allocated towards R&D activities, and 35% of the profit was attributed to marketing activities, which the TPO had adopted in the present case, and therefore the same is just and reasonable. Referring to para 9 of the order of the TPO, he submitted that even after a specific request of the TPO to furnish financial statements of all affiliates engaged in marketing and distribution activities, the Assessee failed to furnish such details despite the prescription u/s 92D(3) of the Act.

8.

We have given our thoughtful consideration and perused the materials on record. There is no dispute that the facts of the present case in respect of the issue in dispute are identical to that of Assessment Year 2013- 14, and the TPO has adopted the reasoning of Assessment Year 2013-14

- 18– itself. Ld. DRP has also followed its directions for Assessment Year 2013- 14. In the case of Assessment Year 2013-14, Ld. DRP has upheld the adjustment made by the TPO, by observing as under:

“12.1. We have considered the matter in detail and have considered the findings of the TPO and submissions of the assessee. Since all the grounds above relate to the same issue of the TP adjustment to the price that should have been received by the assessee, they are being dealt with together.

12.2 The TPO's key findings are as under:

"5. As far as the selection of tested party is concerned, it can be seen from the above FAR analysis that the assessee (ZHOPL) is carrying complex functions whereas the AE (HEBV) is carrying out only marketing functions. The assessee is owning most crucial and valuable intangibles in the form IPR and USFDA/UK/Canada approved manufacturing facility, whereas the AE is claimed to having only trade mark intangibles. Even for this no proof is filed After considering the ownership of such intangibles. the AE is less complex entity than the Indian entity i e the assessee. Therefore it is proposed to select AE as tested party for benchmarking the ALP of sale transaction. The another reason for selecting the AE as tested party is that the assessee is being compensated at cost plus 20%, whereas the margin on cost earned by the AE varies is substantially high. Though the assessee has not furnished the financial statements of AE, it has submitted the details of true up charges received from AE along with the details of sales made by AE, on the basis of which it is clear that the margins earned by the AE are substantially higher than the cost mark up of 20%. Therefore, it is necessary to see as to whether the transaction with the AE are at ALP or otherwise. In such a scenario ideally the AE is proposed to be selected as tested party and the benchmarking analysis carried out by the assessee, taking assessee as tested party and selection of Indian comparables is thus rejected. Further your reliance on the decision of Hon'ble ITAT Hyd bench in the case of M/s Satyam Venture Engg. Services Pvt. Ltd. would be of no help as in that case the issue under adjudication was whether SCSL could in view of the JV agreement be held to be an affiliate of Venture which in your context would mean whether CPL could in view of the JV agreement

- 19– be held to be an affiliate of Hospira and this is not the issue at hand in your case. Further the said decision is not a binding precedent.

6.

However as no financials of the AE HEBV or any other AEs involved in the chain after ZOHPL to the customers have been furnished the undersigned is unable to do the benchmarking of the transaction of the assessee company with HEBV by using TNMM and by taking HEBV as the tested party. In these circumstances as in AY 2012-13 the undersigned proposes to use PSM method since the international transaction involves utilization of unique intangibles such as IPRI Trademark/technology through license distribution agreement and master supply agreement between the AEs/ partners of joint venture As discussed in Para 4 above the most of the assets are used by the assessee. The major functions are undertaken by the assessee and substantial part of risks is also borne by the assessee only, except the inventory risk and use of marketing intangibles by the AE. Yet as the truing up exercise shows the AE has enjoyed substantially high profits cost for only marketing/distribution functions whereas assessee is getting only 50% consideration of net sales though it performs entire manufacturing activity and major portion of the risk lies with him Therefore it is proposed to split the combined profit earned by the assessee and AE in the ratio of 65:35 based on decision of the Hon'ble ITAT. New Delhi in the case of Mis Rolls Royce Pic (ITA no 1496 to 1501/ DEL of 2007 for AY 1997-98 to 2000-01, 2002-03 & 2003-04)'

7.

The assessee company filed its reply to the Show Cause Notice vide letter dated 18.10.2016. The main contentions made by the assessee company are those already are dealt in detail in the order for the A.T.2012-13. These contentions are not repeated here and reliance is placed on the discussion in the order of A.Y.2012-13. In the present submissions the assessee company has taken additional contentions relying on the decision of the Hon'ble ITAT Hyderabad bench in the case of M/s.Satya Venture Engg Services Pvt.Ltd. Vs. ACIT (ITA No.1590/HYD/2010). On the basis of the said decision it was contended that transactions done on the basis of the pricing arrangement agreed between independent JV partners should perforce be taken to be at arm's length. The said decision has been perused and the same is found to be of no help to the assessee's cause. In the case before Hon'ble ITAT the issue under adjudication was whether SCSL (in our case say Cadila Healthcare Limited) could in view of the JV

- 20– agreement (formation of ZHOPL) be held to be an affiliate of Venture (in our case say Hospira Australia Pty Limited). On this issue the ITAT held that even after the JV formation SCSL and Venture were not related parties i.e. AEs. As against this the transactions being benchmarked in our case are not between Cadila Healthcare Limited and Hospiral Australia Pty Limited but are those between the JV i.e. ZHOPL and subsidiary of Hospira Australia Pty Limited i.e. HEBV. These are transactions between AEs as 50% holding of the JV was in the hands of Hospira Australia Pty Limited.

Calculation of Residual Profit:

7.

For the purpose of calculation of combined profit of all AEs from sale of these 6 drugs, their financials were needed which have not been made available. The assessee was requested to furnish financial statements of all affiliates engaged in marketing and distribution activity. However, the assessee failed to furnish such details. Since as per LDA agreement, the 'net sales'figure has been arrived at by the assessee after reducing the selling and distribution expenses, no deduction for such expenses is required to be considered in the computation of residual profit for allocation. Last year the financial of HEBV for the period ending on December 2011 were furnished before the TPO. As per these the wages and salary expenses and social security contributions of 3067 (000) Euros were found debited in terms of percentage it came to 4.52% of sales. This year even the financials of HREV have not been filed. In absence of financial statements for the affiliates, a deduction of 4.52% on the basis of the financials furnished during AY 2012-13 is allowed on account of wages and salary expenses and social security contributions.

Allocation of Residual Profit

In AY 2012-13 relying on the decision of Hon'ble ITAT. New Delhi in the case of M/s Rolls Royce Pic (ITA no. 1496 to 1501/DEL of 2007 for AY 1997-98 to 2006-to 50% of 01.2002-03 & 2003-04) profit allocation of 65% to JV ie assessee company and 35% the profits towards manufacturing activity, 15% of the profit allocated towards R & D activity and 35% of the profit was attributed to marketing activities. Following the principles laid down by the Hon'ble ITAT, the profit earned by the assessee, AE and affiliates in the manufacturing and distribution activity is allocated into 65 35 ratio i.e. 65% of the - 21– profit is attributed to the assessee since the manufacturing activity has been carried out by the one member of JV namely Cadila Healthcare Ltd. by using the manufacturing related IPRs and the another member of JV i.e. Hospira Australia Pte. Ltd. is owner of product related IPR and IPR relating to Para IV USFDA approval. Thus, in line with AY 2012-13 the manufacturing and R & D activities are carried out by the two members of joint venture and therefore 65% of the profit (50% + 15%) is attributed to the assessee and the balance profit of 35% is attributed to the Hospira Enterprises BV (HEBV) and affiliates for carrying out the distribution Le. marketing activity."

12.3 The TPO allocated the profit in the ratio of 65% to 35% following the decision of Hon'ble ITAT, New Delhi in the case of M/s.Rolls Royce Plc. According to this decision, the profits are to be allocated in the following ratio:

i) 50% to manufacturer ii) 15% towards R&D iii) 35% for marketing activity.

12.4 If we go through the agreement dated 25.09.2008, M/s.Hospira Enterprises B.V. was referred as Licensee.

(a) It is further mentioned in the agreement that licensee carries on the business of storing, distribution and selling finished medicinal products and other things. This clearly shows that the only function of HEBV was related to marketing. So it can rightfully claim only the profit related to the marketing.

Further, the agreement itself shows why the assessee was entitled to the profit related (b) to the R&D. Para 11.2 of this agreement shows that the intellectual property rights of the products were owned by the assessee. For clarity, the same is reproduced below :-

"(a) Licensee acknowledges that, subject to the following paragraphs, the Company owns all right, title and interest in all Intellectual Property Rights in the Product (excluding Background Intellectual Property).

(b) The Company acknowledges that Licensee owns all right, title and interest in all Intellectual Property Rights generated in connection with the storage, promotion, sale and distribution of the Product in the - 22– Hospira Territory (including all Intellectual Property Rights in the Licensee Trade Marks)."

The share of R&D is directly related to owning of Intellectual Property Rights. As the assessee owned the Intellectual Property Rights, we are of the opinion that 15% of the profit allocated towards R&D activity was attributable to assessee. The same was done by the TPO.

(c) Considering the above, we agree with the adjustments made by the TPO who has been very reasonable in allocating the entire marketing profit to the AE and reject the objection raised by the assessee.”

9.

As regards the first submission, we find that the method adopted by the Assessee cannot be sustained in the facts of the present case. The Assessee has treated its adoption of 2005 agreement as, and claimed it to be, 'Other Method' in terms of Section 92C(1)(f) of the Act. Section 92C(1) of the Act reads as under:

“Section 92C(1) in The Income Tax Act, 1961 (1) The arm's length price in relation to an international transaction shall be determined by any of the following methods, being the most appropriate method, having regard to the nature of transaction or class of transaction or class of associated persons or functions performed by such persons or such other relevant factors as the Board may prescribe, namely:- (a) comparable uncontrolled price method; (b) resale price method; (c) cost plus method; (d) profit split method; (e) transactional net margin method; (f) such other method as may be prescribed by the Board.”

10.

The Hon'ble Bombay High Court in the case of CIT vs. Kotak India Pvt. Ltd., reported in (2017) 79 taxmann.com 369 (Bombay), observed as under: “10. We must also record the fact that the ALP was arrived at by the Transfer Pricing Officer (TPO) by not adopting any of the methods prescribed under section 92C of the Act. The method to determine

- 23– the ALP adopted was not one of the prescribed methods for computing the ALP. It was not even any method prescribed by the Board. At the relevant time, i.e. for A.Y. 2008- 09 Section 92C of the Act did not provide for other method as provided in Section 92C(1)(f) of the Act. The impugned order of the Tribunal holds that the method adopted by the Revenue to determine the ALP was alien to the methods prescribed under Section 92C of the Act. In the above circumstances, the Tribunal declined to restore the issue to the Assessing Officer for re- determining the ALP by adopting one of the methods as listed out in Section 92C of the Act. This finding of the Tribunal has also not been challenged by the Revenue.

11.

In view of the fact that the Revenue has accepted the order of the Tribunal on its findings on facts on the two issues as pointed out hereinabove as well as the refusal of the Tribunal to restore the issue of determination of ALP to the TPO by following one of the methods prescribed under the issue of determination of ALP to the TPO by following one of the methods prescribed under Section 92C of the Act. Thus, the question as formulated for our consideration even if answered in favour of the Revenue would become academic in the present facts. Thus, we see no reason to Assessment Year: 2012-13 entertain this appeal. However, we make it clear that the issues of law which has been raised in the present appeal are left open for consideration in an appropriate case.” Emphasis supplied. 11. Thus, the Hon'ble High Court approved the finding of the Co- ordinate Bench of the Tribunal to the effect that the method adopted to determine ALP has to be any of the methods prescribed u/s 92C of the Act. Section 92C(1)(f) of the Act provides for such other method prescribed by the Board. The Assessee in the present case has not claimed that the method adopted by it was prescribed by the Board as 'Other Method' u/s 92C(1) of the Act. Therefore, the determination of ALP proposed by the Assessee cannot be sustained in the present case.

- 24– 12. The Assess in their transfer pricing documentation has primarily relied upon the JVA entered in 2005 between CHL and HAPL, which were then unrelated parties. Later on, due to change of management and controlling stakes, the Assessee and HAPL are now associated enterprises. Once the parties to the transaction are associated enterprises in terms of Section 92B, Section 92 of the Act mandates determination of income of the international transaction involved among the associate enterprises on the basis of Arms Length Price (ALP). The adoption of the year 2005 data by the Assessee is flawed on two counts. Firstly, the management and control of companies, who were parties to the agreement has undergone change making them unsuitable for compatibility analysis. Secondly, Rule 10B(4) of the Income Tax Rules, 1962 (the Rules) mandates comparability of uncontrolled transaction on the basis of current year data. Proviso thereto permits data relating to a period not being more than two years prior to the current year only.

13.

In terms of Section 92CA(3), the TPO in the present case has chosen PSM as the Most Appropriate Method for determination of ALP in accordance with the mandate of Section 92C(1) of the Act. Transactional profit split method is a transfer pricing method that is based on the concept of splitting the combined profits of a transaction between related parties in a similar way as how independent parties would under comparable circumstances. The Profit Split Method is typically applied when both sides of the controlled transaction contribute significant intangible property. The profit is to be divided such as is expected in a joint venture relationship. The Profit Split Method seeks to eliminate the effect on profits of special conditions made or imposed in a controlled transaction (or in controlled transactions that it is appropriate to aggregate) by determining the division

- 25– of profits that independent enterprises would have expected to realize from engaging in the transaction or transactions. The Profit Split Method starts by identifying the profits to be divided between the associated enterprises from the controlled transactions. Subsequently, these profits are divided between the associated enterprises based on the relative value of each enterprise's contribution, which should reflect the functions performed, risks incurred and assets used by each enterprise in the controlled transactions. Also, the TPO, by virtue of Section 92CA(3), is bestowed with the responsibility to determine the arm’s length price in relation to the international transaction after taking into account all the relevant materials on record.

14.

Since the transaction in question is governed by the LDA of the year 2008 entered into between the Assessee and Hospira, wherein the rights and duties of the parties were clearly demarcated, the adoption of PSM by the TPO cannot be faulted. We also take notice of the fact that the Assessee in the present case has not fully cooperated with the Ld. TPO, inasmuch as the Assessee has not supplied the requisite details or documents despite a specific request from the Ld. TPO. As was the case in Assessment Year 2013-14, in the present case also, the Assessee has not made available the required financial details, which is evident as per para 9 of the order of the Ld. TPO, which reads as under: “9. For the purpose of calculating the combined profit of all AEs from sale of these 6 drugs, their financials were required which have not been made available by the assessee. The assessee was specifically requested to furnish financial statements of all affiliates engaged in marketing and distribution activity. However, the assessee failed to furnish such details. Since, as per LDA agreement, the 'net sales' figure has been arrived at by the assessee after reducing the selling and distribution expenses, no deduction for such expenses is required to be considered in the computation of residual profit for allocation. It is also noticed that in the preceding financial year, the assesse

- 26– had furnished the financials of HEBV for the period ending on December 2011 before the TPO. As per these the wages and salary expenses and social security contributions of 3067 (000) Euros were found debited. In terms of percentage it came to 4.52% of sales. This year even the financials of HBEV have not been filed. In absence of financial statements for the affiliates, a deduction of 4.52% on the basis of the financials furnished during AY 2012- 13 is allowed on account of wages and salary expenses and social security contributions.” 15. The conduct of the Assessee is against the mandate of Section 92D(3) of the Act. In view of the foregoing, we find no infirmity in the TPO selecting PSM as the MAM in the facts of the present case.

16.

As regards the contention regarding the adoption of the 65:35 profit split ratio, we find that the Tribunal in the case of Rolls Royce (supra) has allocated 50% of the profit towards manufacturing activities, 15% of the profit allocated to R&D activities, and 35% of the profit was attributed to marketing activities in the said case. However, this allocation cannot be applied universally. There can never be a strait jacket formula for allocation of profit, which will fit the facts and circumstances of every case. However, in the facts of the present case, where the Assessee is performing the manufacturing activities entirely and Hospira is only a licensee having only the function of marketing the product, Hospira can rightly claim the profit relating to marketing.

16.1. In the facts of the present case, additionally in view of the non- cooperation in furnishing details sought for by the TPO, the adoption of the formula given in Rolls Royce (supra) cannot be faulted. Determination of ALP is not an exact science. It is only a method of approximation to determine the arm’s length price in a given case on the basis of materials available on record before the TPO.

- 27–

17.

Ld. DRP, while approving the split made by TPO, has observed, as under: “12.3 The TPO allocated the profit in the ratio of 65% to 35% following the decision of Hon'ble ITAT, New Delhi in the case of M/s.Rolls Royce Plc. According to this decision, the profits are to be allocated in the following ratio:

i) 50% to manufacturer

ii) 15% towards R&D

35% for marketing activity.

12.4 If we go through the agreement dated 25.09.2008, M/s.Hospira Enterprises B.V. was referred as Licensee.

(a) It is further mentioned in the agreement that licensee carries on the business of storing, distribution and selling finished medicinal products and other things. This clearly shows that the only function of HEBV was related to marketing. So it can rightfully claim only the profit related to the marketing.

Further, the agreement itself shows why the assessee was entitled to the profit related (b) to the R&D. Para 11.2 of this agreement shows that the intellectual property rights of the products were owned by the assessee. For clarity, the same is reproduced below :-

"(a) Licensee acknowledges that, subject to the following paragraphs, the Company owns all right, title and interest in all Intellectual Property Rights in the Product (excluding Background Intellectual Property).

(b) The Company acknowledges that Licensee owns all right, title and interest in all Intellectual Property Rights generated in connection with the storage, promotion, sale and distribution of the Product in the Hospira Territory (including all Intellectual Property Rights in the Licensee Trade Marks)."

- 28– The share of R&D is directly related to owning of Intellectual Property Rights. As the assessee owned the Intellectual Property Rights, we are of the opinion that 15% of the profit allocated towards R&D activity was attributable to assessee. The same was done by the TPO. (c) Considering the above, we agree with the adjustments made by the TPO who has been very reasonable in allocating the entire marketing profit to the AE and reject the objection raised by the assessee.”

18.

As rightly noticed by the Ld. DRP in its order for Assessment Year 2013-14 at para 12.4, the Assessee owned the intellectual property rights of the transaction. In view of that, 15% of the profit allocated towards R&D activities was attributed only to the Assessee. Further, the entire manufacturing activity was carried out by the Assessee and, therefore, 50% of the profit allocated towards manufacturing activity was also attributed only to the Assessee. In essence, the role of Hospira was limited to marketing of the product and, therefore, 35% of the profit, is allocated towards marketing, was entirely attributed to Hospira. We, therefore, find the allocation of 65:35 made by the TPO, was in order and, accordingly, uphold the same.

19.

In view of the foregoing discussions, Ground No. 1 raised by the Assessee is dismissed.

20.

Mr. Soparkar, Ld. Senior Advocate, submits that Ground No. 2, regarding depreciation on computer software restricted by the AO by treating software as an intangible asset and allowing depreciation at 25%/12.5% instead of 60%/30%, is covered by the decision of this Tribunal in the case of the Assessee itself for Assessment Year 2010-11 and - 29– Assessment Year 2011-12. This fact is not disputed by the Ld. CIT-DR. Following the said decision, we accordingly allow the present ground.

21.

Ground Nos. 3 and 5 are not pressed by the Ld. Senior Advocate. Hence, Ground Nos. 3 and 5 are dismissed as not pressed.

22.

Ground Nos. 4 and 6, regarding levy of interest u/s 234B and 234A, as well as Ground No. 7, regarding levy of penalty proceedings u/s 270A, are consequential in nature and, therefore, require no adjudication.

ITA No. 1521/AHD/2024 (Assessment Year 2020-21): 23. The grounds raised in the present Appeal are as under: “1. Ground 1 On the facts and in the circumstances of the case and in law, the Assessment Unit, Income Tax Department ('the Ld. AO') under the directions of Honourable Dispute Resolution Panel (DRP), erred in making an adjustment of INR 28,52,00,000/-in relation to the international transaction of sales to the Associated Enterprise (AE) under Licence Distribution Agreement.

On the facts and in the circumstances of the case and in law, the Ld. AO has erred in following: 1.1 Disregarding that the pricing mechanism incorporated in Licence Venture Partners [i.e. Cadila Healthcare Limited, now Zydus Lifesciences Limited (CHL) and Hospira Australia Pty Limited (HAPL)] in the Joint Venture Agreement (JVA) and the same should be considered at arm's length.

1.2 Stating that JV Partners lose their individual status once they represent in the form of ZHOPL (ie. JV) and attributing rewards to ZHOPL for Research and Development (R&D) functions and Product Intellectual Property (IP) of HAPL.

1.3 Holding the appellant as the owner of the most crucial and valuable intangibles and wrongly attributed reward for the same to the Appellant.

- 30– 1.4 Not observing the overall value chain of the business and incorrectly concluded that the AEs are merely engaged in distribution activities and they should be rewarded only for distribution function.

1.5 Considering the Appellant's approved (approved by USFDA, Health Canada and MHRA, UK) manufacturing facility as significant intangible asset.

1.6 Rejecting the Appellant's approach of adopting Other Method as the most appropriate method, in the Transfer Pricing (TP) Study/Documentation.

1.7 In considering Profit Split Method (PSM) as the most appropriate method to determine Arm's Length Price of international transaction of sale of six formulations products to HEBV.

1.8 Arbitrarily applying Rolls Royce Ple ruling (M/s Rolls Royce Plc vs The Dy. Director of Income Tax, New Delhi, 2007-TII-32-ITAT-DEL-INTL) to the Appellant's case fact pattern and allocated profit in the ratio of 50:15:35 for manufacturing function, R&D activity and marketing activity respectively.

1.9 Without prejudice to the above, on the facts and in the circumstances of the case and in law, the Ld. A.O. erred in applying PSM;

1.9.1 Not undertaking a fresh benchmark as required by India Transfer pricing regulation and relying on the same comparables selected by the Ld. Transfer Pricing Officer in AY 2012-13-

1.9.2 By considering comparables engaged in incomparable business activities to that of AEs and only from one jurisdiction, ie. Netherland, against Appellant's AEs, located in different geographical regions viz. Europe, USA etc.

The Appellant prays that the addition made by the Ld. A.O. in relation to the international transaction of sales to AE is to be deleted.

2.

Ground 2 On the facts and in the circumstances of the case and in law, the learned AO erred in law and on facts in adding transfer pricing adjustment proposed by the Ld. TPO of INR 28,52,00,000/- to the book profit computed for the purpose of computing minimum alternate tax under section 115JB of the Act without giving any reason for the same in the Assessment Order.

- 31–

3-Ground 3 On the facts and in the circumstances of the case and in law, the learned AO has failed to appreciate the provisions of the Income tax Act that the book profit of the company cannot be adjusted except as provided in Explanation 1 of Section 115JB(2) and that transfer pricing adjustment is not one of the adjustments provided under that explanation.

4.

Ground 4 On the facts and in the circumstances of the case and in law, the learned AO erred in law and on facts in not giving in the tax computation, the set-off of MAT Credit u/s. 115 JAA of earlier years to which the Appellant is lawfully entitled to in view of it being covered under the provisions of MAT u/s 115JB.

5.

Ground 5 On the facts and in the circumstances of the case and in law, the learned AO erred in law and on facts in charging interest u/s. 234A of INR 23,36,439/-.

6.

Ground 6 On the facts and in the circumstances of the case and in law, the learned AO erred in law and on facts in charging interest u/s. 234B of INR 3,97,19,463/-.

7.

Ground 7 On the facts and in the circumstances of the case and in law, the learned AO erred in law and on facts in charging interest u/s. 234D of INR 1,53,871/-

Each ground of objection is without prejudice to and independent of each other.

The Appellant craves leave to add, to alter, to amend, to substitute, to modify and/or withdraw all or any of the Grounds of Appeal herein and to submit such statements, documents and papers as may be considered necessary either at or before the appellate hearing.

Additional Ground “Without prejudice to the grounds already raised in the Appeal memo, the Appellant submits that: 1. On the facts and in the circumstances of the case and in law, the assessment order passed under section 143(3) read with section 144C(13) and read with section 144B of the Act, having been passed beyond the period of - 32– limitation provided under section 153 of the Act, is without jurisdiction and void-ab-initio, illegal and bad in law and is therefore liable to be quashed. The Appellant prays that the assessment order be quashed, and the entire addition made by the Ld. AO/Ld. TPO be deleted. The Appellant craves leave to add, substitute, amend, delete, or otherwise modify any of the grounds of appeal stated hereinabove before commencement of or at the time of hearing.”

24.

Both the parties agreed that Ground No. 1, relating to the transfer pricing adjustment on international transaction of sales to AE under LDA, is identical to Ground No. 1 of ITA No. 87/AHD/2022 relating to Assessment Year 2017-18 and, therefore, our decision in the said case will apply mutatis mutandis to the present ground as well. Following our decision in ITA No. 87/AHD/2022, the ground raised by the Assessee is dismissed.

25.

Ground Nos. 2, 3, and 4 are not pressed by the Ld. Senior Advocate, as the AO has passed a rectification order u/s 154 rectifying the computational errors in the Assessment Order. The said grounds are accordingly dismissed as not pressed by the Ld. Senior Advocate.

26.

Ground Nos. 5 to 7, relating to levy of interest u/s 234A, 234B, and 234D, are consequential in nature and require no adjudication.

27.

In the result, the present appeal, i.e., ITA No. 1521/AHD/2024 for Assessment Year 2020-21, filed by the Assessee, is dismissed.

ITA No. 2123/AHD/2024 (Assessment Year 2021-22): 28. The grounds raised in the present Appeal are as under: “1. Ground 1

- 33– On the facts and in the circumstances of the case and in law, the assessment order passed under section 143(3) read with section 144C(13) and read with section 144B of the Act, having been passed beyond the period of limitation provided under section 153 of the Act, is without jurisdiction and void-ab- initio, illegal and bad in law and is therefore liable to be quashed.

The Appellant prays that the final assessment order is liable to be quashed.

Without Prejudice to the above;

2 Ground 2. On the facts and in the circumstances of the case and in law, the Assessment Unit, Income Tax Department (the Ld. AO') under the directions of Honourable Dispute Resolution Panel (DRP), erred in making an adjustment of INR 45,61,00,000/-in relation to the international transaction of sales to the Associated Enterprise (AE) under Licence Distribution Agreement.

On the facts and in the circumstances of the case and in law, the Ld. AO has erred in following:

2.1 Disregarding that the pricing mechanism incorporated in Licence Venture Partners [i.e. Cadila Healthcare Limited, now Zydus Lifesciences Limited (CHL) and Hospira Australia Pty Limited (HAPL)] in the Joint Venture Agreement (JVA) and the same should be considered at arm's length.

2.2 Stating that JV Partners lose their individual status once they represent in the form of ZHOPL (i.e. JV) and attributing rewards to ZHOPL for Research and Development (R&D) functions and Product Intellectual Property (IP) of HAPL.

2.3 Holding the appellant as the owner of the most crucial and valuable intangibles and wrongly attributed reward for the same to the Appellant.

2.4 Not observing the overall value chain of the business and incorrectly concluded that the AE are merely engaged in distribution activities and they should be rewarded only for distributi function.

2.5 Considering the Appellant's approved (approved by USFDA, Health Canada and MHRA manufacturing facility as significant intangible asset.

- 34–

2.6 Rejecting the Appellant's approach of adopting Other Method as the most appropriate method, in the Transfer Pricing (TP) Study/Documentation.

2.7 In considering Profit Split Method (PSM) as the most appropriate method to determine Arm's Length Price of international transaction of sale of six formulations products to HEBV.

2.8 Arbitrarily applying Rolls Royce Fle ruling (M/s Rolls Royce Ple vs The Dy. Director of Income Tax, New Delhi, 2007-TII-32-ITAT-DEL-INTL) to the Appellant's case fact pattern and allocated profit in the ratio of 50:15:35 for manufacturing function, R&D activity and marketing activity respectively.

2.9 Without prejudice to the above, on the facts and in the circumstances of the case and in law, the Ld. A.O. erred in applying PSM;

2.9.1 Not undertaking a fresh benchmark as required by India Transfer pricing regulation and relying on the same comparables selected by the Ld. Transfer Pricing Officer in AY 2012-13. 2.9.2 By considering comparables engaged in incomparable business activities to that of AEs and only from one jurisdiction, ie. Netherland, against Appellant's AEs, located in different geographical regions viz. Europe, USA etc.

The Appellant prays that the addition made by the Ld. A.O. in relation to the international transaction of sales to AE is to be deleted.

3.

Ground 3 On the facts and in the circumstances of the case and in law, the learned AO has inadvertently considered total income of INR 55,19,77,710 as per intimation processed u/s 143(1) instead of correct income of INR 55,19,17,250 as per Return of Income filled by the assessee.

4.

Ground 4 On the facts and in the circumstances of the case and in law, the learned AO erred in concluding that the Appellant has furnished inaccurate particulars of income, and hence directed to initiated penalty proceedings u/s 270A.

5.

Ground 5

- 35–

On the facts and in the circumstances of the case and in law, the learned AO erred in law and on facts in charging interest u/s. 234A of INR 53,04,556/-.

6.

Ground 6 On the facts and in the circumstances of the case and in law, the learned AO erred in law and on facts in charging interest u/s. 234B of INR 5,70,23,977/-

7.

Ground 7

On the facts and in the circumstances of the case and in law, the learned AO erred in law and on facts in charging interest u/s. 234D of INR 15,717/-

Each ground of objection is without prejudice to and independent of each other.

The Appellant craves leave to add, to alter, to amend, to substitute, to modify and/or withdraw all or any of the Grounds of Appeal herein and to submit such statements, documents and papers as may be considered necessary either at or before the appellate hearing.”

29.

Ground Nos. 1 and 3 are not pressed by the Ld. Senior Advocate. Accordingly, the said grounds are dismissed as not pressed. Ground No. 2 relating to the transfer pricing adjustment on international transaction of sales to AE under LDA, is identical to Ground No. 1 of ITA No. 87/AHD/2022 relating to Assessment Year 2017-18 and, therefore, our decision in the said case will apply mutatis mutandis to the present ground as well. Following our decision in ITA No. 87/AHD/2022, the ground raised by the Assessee is dismissed.

30.

Ground No. 4, relating to penalty proceedings u/s 270A. Ground Nos. 5 to 7 are relating to levy of interest u/s 234A, 234B, and 234D, are consequential in nature and require no adjudication.

- 36– 31. In the result, the present appeal filed by the Assessee is dismissed.

32.

In conclusion, ITA No. 87/AHD/2022 is partly allowed, whereas ITA No. 1521/AHD/2024 and ITA No. 2123/AHD/2024 are dismissed.

The order pronounced on 03.11.2026. (DR. B.R.R. KUMAR) (SANJAY KUMAR) VICE-PRESIDENT JUDICIAL MEMBER Ahmedabad; Dated 03 .11.2026 DS, PS JEETENDRA Digitally signed by JEETENDRA DEVENDRABHAI UPADHYAY DN: c=IN, o=PERSONAL, title=6087, 2.5.4.20=7e5568a89b633f174b28a8 DEVENDRA 0f5e63c638da40b7313fb47ebaefda 841cf59d1703, postalCode=380059, st=Gujarat, BHAI serialNumber=816dc56e896211a1a 21ccc4abc94ddc94458f4a1b37be8e 1854e9399295106d4, UPADHYAY cn=JEETENDRA DEVENDRABHAI UPADHYAY Date: 2026.11.05 11:04:10 +05'30'

- 37–

आदेश की "ितिलिप अ"ेिषत / Copy of the Order forwarded to : 1. अपीलाथ"/ The Appellant 2. ""थ"/ The Respondent. 3. संबंिधतआयकरआयु"/ Concerned CIT आयकरआयु"(अपील) /The CIT(A)- 4. 5. िवभागीय"ितिनिध, आयकरअपीलीयअिधकरण, अहमदाबाद/ DR, ITAT, Ahmedabad गाड"फाईल /Guard file. 6. आदेशानुसार/ BY ORDER,सहायकपंजीकार (Dy./Asstt.

More judgments on Section 32

All 3,161 judgments and leading authorities on Section 32 →

Recent GST High Court judgments

Search GST case law →